

INDEX

Note: AD stands for Atopic Dermatitis.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

- Adolescent-onset AD, 67, 70, 71
- ADSI (AD Severity Index), 101
- Adult-onset AD, 10-12, 14, 67
 - clinical presentation, 70-72, 71
- Aeroallergens, 29-30
- African-Americans, AD presentation in, 81-83, 81
- Age of onset, 12, 65, 68-70
 - adolescents and adults, 70-72, 71, 91
 - childhood AD, 68-69
 - infantile AD, 68, 70
- Air pollutants, 49-50
 - indoor, 49
 - outdoor, 49-50
- Alclometasone dipropionate, 150t
- Alcohol, consumption during pregnancy, 41
- Allergens, 41
 - aeroallergens, 29-30
 - air pollutants, 49-50
 - penetration of, 21, 122
- Allergic diseases
 - allergic contact dermatitis, 74-75, 74
 - hygiene hypothesis and, 44-45
 - IgE and, 29
 - serial occurrence of (atopic march), 33, 199
- Allergic salute, 66
- Allergic sensitization, 119-122
- Allergies
 - allergic respiratory disease, 64
 - food allergies, 93-94, 119
 - testing for, 53, 93-94
- Alternative medicine. See *Complementary and alternative therapy*.
- American Academy of Dermatology, 246
- Antibiotics
 - not normally warranted, 70
 - prenatal, maternal exposures to, 40
 - systemic
 - AAD recommendations for, 184t, 201
 - concurrent with topical steroids, 184t
- Antihistamines
 - oral/systemic, 201-203
 - AAD recommendations for, 184t, 203
 - adverse effects, 202
 - indications for short-term use, 203
 - not recommended for AD, 184t, 201, 203
 - topical, 164-165
 - antimicrobials and antiseptics, 164
 - coal tar derivatives, 164-165
- Antimicrobials
 - bleach baths, 43, 146, 234
 - systemic, 200-201
 - topical, 164
- Antiseptics, topical, 164
 - bleach baths, 43, 146, 234
- Antivirals, systemic, AAD recommendations, 184t, 201
- Anxiety, 126
- Apremilast, 199
 - FDA approval for AD, 199
 - treatment-emergent side effects, 199
- Asian patients, 83
- Asthma, 29, 119, 122
 - physical activity and, 134
- Asthma and Allergy Foundation of America, 246
- Atopic comorbidities, 119-124, 120t, 122
- Atopic dermatitis (AD)
 - clinical presentation, 63-86
 - comorbidities, 119-142, 120t-121t
 - diagnosis and evaluation, 87-118
 - environmental risk factors, 39-61
 - epidemiology, 9-19
 - pathogenesis, 21-38
 - severity scales. See *Scoring systems*.
 - treatment of. See *Therapy for AD*.

- Atopic march, 33, 119
 - TSLP as master switch for, 28
- Attention deficit/hyperactivity disorder (ADD/ADHD), 126-127
- Autistic spectrum disorders, 127
- Autoimmune disease, 120t, 129-130
- Ayurveda, 227t
- Azathioprine (AZA), 185-187
 - AAD recommendations for, 184t, 186
 - action mechanism, 185
 - dosage and administration, 187
 - efficacy in AD, 185-186
 - FDA approved for other conditions, 185
 - monitoring guidelines, 188t
 - off-label use in AD, 185-187
 - safety and adverse effects, 186-187
- Barrier dysfunction, 21, 22
 - moisturizer use and, 122-123
- Bath treatments, 146, 162-163
 - AAD recommendations, 148t
 - bleach baths, 43, 143, 146, 234
- Bathing and bath soaps, 43-44, 162-163
- Betamethasone dipropionate, 151t
 - augmented, 151t
- Biofeedback, 227t
- Biologic therapy, 209-224. See also *specific agents*.
 - AD pathogenesis and, 209-211, 210
 - IL-4/IL-13 therapies, 211-218
 - dupilumab (Dupixent), 28, 211-218, 212t
 - therapies not currently recommended for AD, 218-221
 - human IgE, 219-221
 - interleukin 12/interleukin 23 therapies, 218-219
 - ligelizumab, 29, 220
 - omalizumab, 29, 220
 - TNF- α inhibitor (infliximab), 221
 - ustekinumab, 219
- Biomarkers for AD, 67, 91-94
- Bleach baths, 43, 143, 146, 234
- Blood pressure, 133, 136-137
- BMS-981164, 212t
- Bone mineral density (BMD), 128-129
- Breast-feeding, 53
- Calcineurin inhibitors. See *Topical calcineurin inhibitors (TCIs)*.
- CAMs. See *Complementary and alternative therapy*.
- Cancer, 121t, 131-132
 - cutaneous T-cell lymphoma (CTCL), 75, 76, 91
 - lymphomas, 131
 - PUVA and, 172
 - topical calcineurin inhibitors and, 156
- Cardiovascular risk and disease, 121t, 135-138, 136-137
 - sleep disturbance and, 133-134
- Cataracts, 65, 88t, 178
- Cheilitis, 65, 88t
- Childhood AD, 68-69
 - clinical presentation, 68-69
 - disease improvement and clearance, 68
 - prevalence of, 9-10, 11-14
 - severe, 12-14, 15
- Children's Dermatology Life Quality Index (CDLQI), 110
- Chinese Herbal Medicine (CHM), 230
- Cigarette smoke, 41
- Climate influence on AD, 45-49, 46
 - humidity, 32, 47
 - latitude and, 48
 - precipitation, 48-49
 - temperature, 45-47
 - ultraviolet radiation, 47-48
- Clinical outcome assessments, 112-113
- Clinical presentation of AD, 63-86
 - age of onset, 65, 68-70
 - adolescents and adults, 70-72, 71, 91
 - childhood AD, 68-69
 - infantile AD, 68, 70, 89
 - characteristics of clinical presentation, 68-72
 - affected areas, 68, 69, 91
 - age of onset, 68-70

- Clinical presentation of AD (*continued*)
- diagnostic features, 63-67
 - allergic salute, 66
 - biomarkers, 67, 91-94
 - comorbidities, 67
 - Hanifin and Rajka criteria, 63-66, 87-89, 88t
 - ichthyosis, 64
 - morphology and distribution, 64
 - personal or family history, 64, 72
 - photosensitivity and hypopigmentation, 66
 - pruritis, 64, 68
 - Type 1 skin test reactivity, 64
 - xerosis, 64
 - differential diagnosis, 72-80, 73t, 89-91
 - contact dermatitis (CD), 74-75, 74
 - cutaneous T-cell lymphoma (CTCL), 75, 76, 91
 - dermatitis herpetiformis (DH), 77-78
 - eczematous drug eruptions, 78, 78
 - hyper-IgE syndromes (HIES), 79
 - nummular dermatitis (ND), 79-80, 80
 - psoriasis, 75-77, 77
 - scabies, 79
 - seborrheic dermatitis (SD), 72-74
 - ethnicity/race, presentation in skin of color, 81-83
 - heterogeneity of, 9, 87
 - patient history, 64, 67
 - subsets of patients, 83
- Clinical strategies, 245-246
- Clobetasol propionate, 151t
- Clocortolone pivalate, 150t
- Clothing, 42-43
- Coal tar derivatives, 164-165
 - UVB and crude coal tar (Goeckerman regimen), 171
- Coconut oil, 230-231
- Colloidal oatmeal, 231
- Comorbidities, 119-142, 120t-121t, 239
 - atopic, 119-124, 120t, 122
 - autoimmune disease, 120t, 129-130
 - cancer, 121t, 131-132
 - cardiovascular risk and disease, 121t, 132-138, 136-137
- Comorbidities (*continued*)
 - infections, 120t-121t, 130-131
 - injuries and fractures, 128-129
 - neuropsychiatric, 120t, 125-128
 - obesity, 132-133, 136-137
- Complementary and alternative therapy, 225-238, 226t-227t
 - active natural ingredients, 230-232
 - Chinese Herbal Medicine (CHM), 230
 - colloidal oatmeal, 231
 - glycerin, 232
 - mustard oil, 232
 - sunflower oil, 231-232
 - virgin coconut oil (VCO), 230-231
 - AD prevalence and, 226t-227t, 228
 - ADD recommendations, 225
 - bleach baths, 234
 - and childhood AD, 225-228
 - common reasons for use, 228, 229t
 - common types of CAMs, 226t-227t
 - diet, 226t, 228
 - dietary supplements, 226t, 228, 232-233
 - efficacy and studies on (historically), 225
 - herbal therapy, 226t, 228
 - homeopathic therapy, 226t
 - massage therapy, 226t
 - probiotics and prebiotics, 233-234
 - safety considerations, 234-235
 - vitamin therapy, 226t, 228
- Conjunctivitis, 65
- Contact dermatitis (CD), 41, 74-75, 74, 91
- Coordinated management of AD, 239-248
 - multidisciplinary team members, 241-244
 - AD specialist, 241-242
 - dietician, 243-244
 - mental health specialist, 243
 - registered nurse/nurse practitioner, 243
 - patient education, 242, 244-245
 - practical clinical strategies, 245-246
 - shared decision making, 240-241, 240t
 - written treatment plan, 242

- Corticosteroids, systemic, 197-199
 - AAD recommendations for, 184t
 - alternative treatments, 198-199
 - dosage and administration, 198
 - efficacy, 197, 198
 - fracture risk and, 129
 - indications
 - antibiotic prophylaxis and dietary supplementation, 198
 - not recommended for continuous usage, 197
 - as transitional therapy in severe AD, 197
 - safety and adverse effects, 197-198
 - tolerability and concerns, 209
- Corticosteroids, topical, 145-152
 - AAD recommendations for, 152, 154t-155t
 - absorption, with different formulations, 145
 - action mechanisms, 145
 - acute treatment with, 147
 - adverse events, 149-152, 154t
 - agents available, 150t-151t
 - in combination with phototherapy, 173
 - in combination with topical calcineurin inhibitors, 156-157, 159t
 - duration of treatment, 149
 - maintenance therapy with, 146
 - potency and formulations of specific agents, 150t-151t
 - selection of, 145-149, 154t
 - “soak and smear” technique, 44, 149
- Cost of AD, 16
- Crisaborole (Eucrisa), 158-162
 - contraindications and cautions, 162
 - dosage and administration, 162
 - efficacy, 158-160, 161
 - FDA approval for AD, 30, 158
 - safety, 160-162
 - treatment-emergent adverse events (TEAEs), 160-162
- CTCL (cutaneous T-cell lymphoma), 75, 76, 91
- Cutaneous T-cell lymphoma (CTCL), 75, 76, 91
- Cyclic AMP (cAMP), 30
 - PDE-4 and, 158, 199
 - PDE-4 inhibitors and, 30
- Cyclosporine A (CSA), 187-190
 - AAD recommendations for, 184t
 - action mechanism, 187
 - dosage and administration, 190
 - efficacy, 187-189
 - indications for, 187
 - monitoring guidelines, 191t
 - safety and adverse effects, 189-190
- Cytokines, 24-25, 30-31, 123, 158
- Decision making, shared, 240-241, 240t
- Dendritic cells, 24, 145, 201
- Dennie-Morgan infraorbital fold, 65, 88t, 124
- Depression, 126
- Dermatitis Family Impact (DFI), 111
- Dermatitis herpetiformis (DH), 77-78
- Dermatology Life Quality Index (DLQI), 109-110
- Desonide, 150t
- Dexamethasone, 150t
- Diabetes, 136-137
- Diagnosis and evaluation, 87-118. See also *Clinical presentation of AD*.
 - AAD recommendations, 91, 92t
 - biomarkers, 91-94
 - IgE, 91-93
 - skin prick test (SPT), 93-94
 - challenges to, 9
 - clinical outcome assessments, 112-113
 - diagnostic criteria, 87-89
 - AAD criteria, 89, 90t
 - associated conditions, 90t
 - basic features, 88t, 89t, 90t
 - exclusionary conditions, 90t
 - Hanifin and Rajka criteria, 63-66, 87-89, 88t
 - revised, 90t
 - minor features, 88t, 89t
 - UK Working Party Criteria, 89, 89t
 - diagnostic features, 63-67
 - differential diagnosis, 72-80, 73t, 89-91
 - contact dermatitis (CD), 74-75, 74, 91

- Diagnosis and evaluation, differential diagnosis (*continued*)
 cutaneous T-cell lymphoma (CTCL), 75, 76, 91
 dermatitis herpetiformis (DH), 77-78
 eczematous drug eruptions, 78, 78
 hyper-IgE syndromes (HIES), 79
 nummular dermatitis (ND), 79-80, 80
 psoriasis, 75-77, 77
 scabies, 79
 seborrheic dermatitis (SD), 72-74, 91
 disease severity scales, 94-113
 AD Severity Index (ADSI), 101
 Children's Dermatology Life Quality Index (CDLQI), 110
 clinical outcome assessments and, 112-113
 concordance of AD signs and symptoms, 111
 concordance of clinician and patient assessments, 112
 Dermatitis Family Impact (DFI), 111
 Dermatology Life Quality Index (DLQI), 109-110
 Eczema Area and Severity Index (EASI), 97-98, 101, 102, 112
 global assessments, 98-100
 Harmonizing Outcome Measures in Eczema (HOME), 95, 103-104
 lesional intensity vs extent, 101-103
 modified EASI (mEASI), 98
 Numerical Rating Scale (NRS)-pruritus, 106-107, 113
 Patient Oriented Eczema Measure (POEM), 108-109, 113
 Patient-Reported Global Severity of AD, 104-105
 Patient-Reported Outcomes (PRO), 103-111
 Quality of Life (QOL) measures, 103-111
 Rajka-Langeland (R-L), 100
 SCORAD (SCORing Atopic Dermatitis), 96, 101, 111-112
 objective SCORAD (oSCORAD), 97
 Short Form-36 Health Survey (SF-36), 107-108
 Six Area Six Sign AD (SASSAD), 100-101, 111
 skin pain, 105
 Visual Analogue Scale (VAS)-pruritus, 105-106
 Visual Response Scale (VRS)-pruritus, 107, 113
 history of AD, 64, 67, 72
 skin of color, presentation and special considerations, 81-83
- Diet, 52-53, 226t, 228, 230-232
 fish in, 52
 Dietary supplements, 232-233
 folic acid (for methotrexate use), 192-194
 Dietician, 243-244
 Diflorasone diacetate, 151t
 Disability, 16
 Dupilumab (Dupixent), 211-218, 212t
 action mechanism, 211
 adverse reactions, 215-218, 216t-217t
 dosage and administration, 218
 efficacy, 213-215, 214t
 FDA approval for AD, 28
 safety, 215-218
 Dupixent. See *Dupilumab (Dupixent)*.
- Eczema, 73t, 90t
 climate influences on, 45-49, 46
 Eczema Area and Severity Index (EASI), 97-98, 101, 102, 112
 Patient Oriented Eczema Measure (POEM), 108-109, 113
 term use, 9
 world prevalence of, 13
 Eczema herpeticum, 45, 130, 201
 Eczematous drug eruptions, 78, 78
 Eczematous lesions, 91
 Elidel cream. See *Pimecrolimus*.
 Environmental risk factors, 39-61, 40t. See also *Allergens*.
 in AD pathogenesis, 32
 air pollutants, 49-50
 breast-feeding, 53
 climate, 45-49, 46
 humidity, 32, 47
 latitude, 48
 precipitation, 48-49
 temperature, 45-47
 ultraviolet radiation, 47-48
 diet, 52-53
 food allergies, testing for, 53
 hygiene hypothesis, 44-45

- Environmental risk factors (*continued*)
 irritants and pruritogens, 40t, 41-44
 clothing, 42-43
 excess bathing, hot water and bath soaps, 43-44
 fragrances, 42
 maternal exposures during pregnancy, 39-41, 40t
 alcohol, 41
 antibiotics, 40
 cigarette smoke, 41, 50
 stress, 39-40
 “outside-in” hypothesis of AD and, 21
 prevention of AD through early moisturization, 54-55
 probiotic and prebiotic supplementation, 54
 skin flora, 40t
 tobacco smoke exposure, 50-51
 urban vs rural living, 51-52
 water hardness, 51
- Epidemiology of AD, 9-19
 age of onset, 12
 challenges of, 9
 cost of AD, 16
 prevalence of AD, 9-12
 adult AD, 10-12, 14
 childhood AD, 9-10, 11-14
 socio-demographic factors and, 14-16, 39
 in United States, by state, 11, 15
 world map of, 13
 severity/severe AD, 12-14, 15
 socio-demographic risk factors, 14-16
 symptoms, 9
- Epidermal barrier dysfunction, 21, 22
- Ethnicity
 AD presentation for skin of color, 81-83, 81
 AD severity and, 14
- Eucrisa (crisaborole), 158-162
 dosage and administration, 162
 efficacy, 158-160, 161
 FDA approval for AD, 30, 158
 safety, 160-162
 treatment-emergent adverse events (TEAEs), 160-162
- Excimer laser, 171
- Eyes, 65-66, 124
 cataracts, 65, 88t, 178
 Dennie-Morgan infraorbital fold, 65, 88t, 124
 orbital darkening, 66, 88t
- Facial pallor/erythema, 66, 88t
- Family history of AD, 22, 64, 67, 72
- Fezakinumab, 212t
- Filaggrin (FLG) gene, mutations, 21, 22, 23, 41, 123
- Fish in diet, 52
- Flares and relapses, 29, 64
 treatment for, 146-147
- FLG loss-of-function mutations, 22, 23, 41, 123
- Fluocinolone acetonide, 150t
- Fluocinonide, 151t
- Folic acid supplementation, 192-194
- Food allergies, 93-94, 122
 testing for, 53, 93-94, 119
- Food intolerance, 66
- Fractures, 128-129
- Fragrances, 42
- GBR 830, 212t
- Gender, and risk of AD, 16
- Genetic risk factors, 21, 22-24
 family history of AD, 22
 FLG mutations, 22, 23, 41, 123
- Glycerin, 232
- Goeckerman regimen, 171
- GSK3772847, 212t
- Hanifin and Rajka criteria, 63-66, 87-89, 88t
 revised, 90t
- Hay fever, 119, 122, 124
 physical activity and, 134
- Herbal therapy, 226t, 228
 Chinese Herbal Medicine (CHM), 230
 Herpes simplex, 45, 65, 88t

- Histamines, 201. See also *Antihistamines*.
 overlapping histaminergic disorders, 203
- History of AD (patient and family), 22, 64, 67, 72
- HOME (Harmonizing Outcome Measures in Eczema), 95, 103-104
- Homeopathic, 226t
- Humidity, 32, 47
- Hydrocortisone, 150t
- Hydrocortisone acetate, 150t
- Hydrocortisone butyrate, 150t
- Hydrocortisone valerate, 150t
- Hygiene hypothesis, 44-45
- Hyper-IgE syndromes (HIES), 79
- Hypertension, 133, 136-137
- Hypnosis, 227t
- Hypo/hyperpigmentation, 66-67
- Ichthyosis vulgaris, 23, 64
- IgE, 29-30, 91-93, 123, 124, 219-221
 antibodies to, 29, 219-221
 elevated levels of, 65, 88t, 91-93
 hyper-IgE syndromes (HIES), 79
 ligelizumab (anti-IgE), 29, 220
 omalizumab (anti-IgE), 29, 212t, 220
- IL-4/IL-13, 21, 25-28, 26
 therapies targeting, 28, 211-218
- IL-9, 31
- IL-12/IL 23 therapies, 218-219
- IL-17, 30-31
- IL-31, 21, 28, 211
- Immune dysregulation in AD, 24, 25-31, 210
 cyclic AMP (cAMP) and phosphodiesterase 4 (PDE-4), 30
 dendritic cells, 24
 IgE, 29-30
 IL-4 and IL-13, 25-28, 26
 IL-31, 28
 infections, 24, 27, 130
 JAK-STAT pathway, 31
 T_h2, T_h17, and T_h22, 30-31
 TSLP, 24, 28-29
- Immune function, hygiene hypothesis, 44-45
- Immunosuppressants, systemic, 183-196
 AAD recommendations, 184t
 agents, 183
 azathioprine (AZA), 185-187
 cyclosporine A (CSA), 187-190
 indications for, 183-185
 infections and, 130
 methotrexate (MTX), 190-196
 mycophenolate mofetil (MMF), 195-196
 tacrolimus, oral, 196
- Infantile AD, 68, 70, 89
- Infections, 24, 32, 120t-121t, 130-131, 200
 cutaneous, 32, 65, 88t, 130
 differential diagnosis of, 73t
 extra-cutaneous, 130-131
 herpes simplex, 45, 65
 hygiene hypothesis, 44-45
Malassezia furfur, 30
S aureus, 27, 30, 32, 45, 65, 130, 200
 systemic, 32
 systemic antimicrobials and, 200-201
- Inflammation
 in AD pathogenesis, 21, 30-31, 209-211
 bone loss and, 129
 environmental irritants and, 41
 “inside-out” hypothesis and, 21
 interplay with skin barrier dysfunction, 24
 phosphodiesterase 4 (PDE-4) and, 158
 polymorphisms of inflammatory genes, 21
 proinflammatory state, 30
- Inflammatory cytokines, 24-25, 158
- Inflammatory skin conditions, 73t
- Infliximab, 221
- Injuries and fractures, 128-129
- “Inside-out” hypothesis of AD, 21
- Interleukins. See *IL entries*.
- Irritants and pruritogens, 40t, 41-44
 clothing, 42-43
 fragrances, 42

- Irritants and pruritogens (*continued*)
 - irritant contact dermatitis, 74-75
 - preservatives, 42
 - soaps, 41, 44
- Itch. See also *Pruritis*.
 - IL-31 and, 28
 - “itch-scratch cycle,” 68
 - “itch that rashes,” 68
 - quality of life, effect on, 27
 - when sweating, 66
- JAK-STAT pathway, 31
- Keratoconus, 65, 88t
- Laser therapy, 171
- Latitude, 48
- Lebrikizumab, 212t
- Lichenification, 68, 70, 88t, 124
- Ligelizumab, 29, 220
- Light therapy. See *Phototherapy*.
- Lymphomas, 131
 - cutaneous T-cell (CTCL), 75, 76, 91
- Malassezia furfur*, 30
- Management of AD. See *Therapy for AD*.
- Maternal exposures during pregnancy, 39-41, 40t
- Mental health comorbidities, 120t, 125-128.
 - See also *Neuropsychiatric comorbidities*.
- Mental health specialist, 243
- Mepolizumab, 212t
- Methotrexate (MTX), 190-196
 - AAD recommendations for, 184t
 - action mechanism, 190
 - dosage and administration, 194-195
 - efficacy, 192
 - FDA approved for other conditions, 190
 - folic acid and, 192-194
 - monitoring guidelines, 193t
 - off-label use in AD, 190-192
 - safety and adverse effects, 192-194
- Moisturizers, 143-144
 - AAD recommendations, 144, 148t
 - actions and benefits of, 143-144
 - in combination with phototherapy, 173
 - efficacy and safety, 143, 144
 - formulations of, 143
 - fragrance-free, 42
 - immediate application after bathing, 43
 - importance of, 43, 54-55, 122-123
 - preservatives and additives in, 42
 - prevention of AD through early use of, 54-55
 - proactive application to at-risk infants, 54-55
- Mometasone furoate, 151t
- Montelukast, 203, 204
- Mustard oil, 232
- Mycophenolate mofetil (MMF), 195-196
 - AAD recommendations for, 184t
 - dosage and administration, 196
 - monitoring guidelines, 196t
 - safety and adverse effects, 195-196
- National Eczema Association, 246
- Neck folds, 66
- Nemolizumab, 212t
- Neuropsychiatric comorbidities, 120t, 125-128
 - anxiety, 126
 - attention deficit/hyperactivity disorder, 126-127
 - depression, 126
 - mechanisms for, 127
 - sleep disturbance, 125-126
 - suicidal ideation, 126
- Nipple eczema, 65, 88t
- Numerical Rating Scale (NRS)-pruritus, 106-107, 113
- Nummular dermatitis (ND), 79-80, 80
- Nurse/nurse practitioner, 243
- Nutritional disorders, 73t
- Oatmeal, colloidal, 231
- Obesity, 132-133, 136-137
- Omalizumab, 29, 212t, 220

- Oral systemic therapy, 183-207. See also *specific therapies*.
 AAD recommendations for, 184t, 186
 phosphodiesterase-4 inhibitor: apremilast, 199
 systemic antimicrobials, 200-201
 systemic corticosteroids, 197-199
 systemic immunosuppressants, 183-196
 azathioprine (AZA), 185-187
 cyclosporine A (CSA), 187-190
 methotrexate (MTX), 190-196
 mycophenolate mofetil (MMF), 195-196
 tacrolimus, 196
 systemic/oral antihistamines, 201-203
 therapies not recommended for AD, 203-204
 tolerability and concerns, 209
 “Outside-in” hypothesis of AD, 21, 22
- Pain
 associated with AD, 9
 skin pain, 105
- Papaverine, 203-204
- Papular eczema, 82-83
- Pathogenesis of AD, 21-38, 209-211
 atopic march, 33
 barrier dysfunction (“outside-in” hypothesis), 21
 environmental factors affecting, 32
 genetic risk factors, 22-24
 family history of AD, 22
 FLG loss-of-function mutations, 22, 23, 123
 immune dysregulation, 25-31, 210
 cAMP and, PDE-4, 30
 dendritic cells, 24
 IgE, 29-30
 IL-4/IL-13, 25-28, 26
 IL-9, 31
 IL-31, 28
 JAK-STAT pathway, 31
 T lymphocyte differentiation, 25, 30-31
 T_h17, and T_h22, 30-31
 TSLP, 28-29
 infections and, 32
- Pathogenesis of AD (*continued*)
 inflammatory response (“inside-out” hypothesis), 21
 “inside-out” hypothesis, 21
 interplay of factors, 24, 129
 “outside-in” hypothesis, 21, 22
 skin barrier dysfunction, 21, 22
 interplay with inflammation, 24
 transepidermal water loss (TEWL), 21, 22
 Patient, shared decision making with, 240-241
 Patient education, 242, 244-245
 Patient Oriented Eczema Measure (POEM), 108-109, 113
 Patient-Reported Outcomes (PRO), 103-111
 PDE-4. See *Phosphodiesterase 4 (PDE-4)*.
 Perifollicular accentuation, 66, 82-83, 82, 88t
 Personal care products, 41-42
 Phosphodiesterase 4 (PDE-4), 30, 158, 199
 cyclic AMP and, 158, 199
 Phosphodiesterase-4 (PDE-4) inhibitors
 oral/systemic: apremilast, 199
 topical, 158-162
 action mechanism, 158
 contraindications and cautions, 162
 dosage and administration, 162
 efficacy, 158-160, 161
 eucrisa (Crisaborole), 30, 158-162
 safety, 160-162
- Photosensitivity, 66
- Phototherapy, 169-181
 AAD guidelines on, 173-175, 174t
 action mechanism, 169, 170-171
 combination therapy with, 173
 dosing guidelines, 174-175, 174t
 BBUVB, 174, 176t
 NBUVB, 174, 177t
 PUVA, 174, 175t
 efficacy, 169, 170, 179
 home phototherapy, 174t, 178-179
 indications for, 169, 174t, 179
 limitations of, 175-177
 pediatric considerations, 175

- Phototherapy (*continued*)
- side effects of, 178
 - tanning beds, 178-179
 - ultraviolet A radiation (UVA), 171-172
 - combination with UVB, 173
 - psoralens and UVA (PUVA), 172
 - safety issues, 172, 175, 178
 - side effects (cataract formation), 178
 - UVA-1, 171-172
 - ultraviolet B radiation (UVB), 169-171
 - broad-band UVB (BBUVB), 169-170
 - combination with UVA, 173
 - excimer laser (308 nm), 171
 - narrow-band UVB (NBUVB), 47, 170-171, 179
 - UVB and crude coal tar (Goeckerman regimen), 171
- Physical activity, 134-135
- Pimecrolimus, 152-158
- in combination with phototherapy (and cautions for), 173
 - dosage and administration, 156-157
 - efficacy, 153
 - indications for, 152
 - safety and adverse events, 153-156, 159t
 - black box warning for malignancy, 156, 159t
 - in treatment algorithm, 146
- POEM (Patient Oriented Eczema Measure), 108-109, 113
- Prebiotic supplementation, 54, 233-234
- Precipitation, 48-49
- Prednicarbate, 150t
- Pregnancy
- alcohol consumption, 41
 - antibiotics during, 40
 - breast-feeding and, 53
 - cigarette smoke exposure, 41, 50
 - environmental risks during, 39-41, 40t
 - stress during, 39-40
- Prescription emollient devices (PEDs), 144-152
- lipid ratios in, 144
 - topical corticosteroids, 145-152
- Preservatives, 42
- Prevalence of AD, 9-12
- adult AD, 10-12, 14
 - childhood AD, 9-10, 11-14
 - severe, in United States (by state), 15
 - socio-demographic factors and, 14-16, 39
- Prevention of AD, through early moisturization, 54-55
- Probiotic supplementation, 54, 233-234
- Protopic ointment. See *Tacrolimus*.
- Pruritis, 9, 64, 68
- associated conditions, 239
 - quality of life and, 27
- Pruritogens, 40t, 41-44
- Psoralens, and UVA (PUVA), 172
- Psoriasis, differential diagnosis of, 75-77, 77, 91
- PUVA (psoralens and UVA), 172
- safety issues, 172, 175, 178
- QGE031, 212t
- Quality of Life (QOL) measures, 103-111
- Children's Dermatology Life Quality Index (CDLQI), 110
 - Dermatology Life Quality Index (DLQI), 109-110
- Race/ethnicity
- AD presentation for skin of color, 81-83, 81
 - and AD prevalence, 14
- Rajka-Langeland (R-L) severity scale, 100
- Resources, 246
- Risk factors for AD, 14-16, 39-61
- environmental risk factors, 39-61, 40t
 - genetic risk factors, 22-24
- S aureus* infection, 27, 30, 32, 45, 65, 88t, 130
- systemic antimicrobials and, 200-201
- SASSAD (Six Area Six Sign AD), 100-101, 111
- Scabies, 79
- SCORAD (SCORing Atopic Dermatitis), 96, 101, 111-112
- objective SCORAD (oSCORAD), 97, 101, 102
- Scoring systems (disease severity scales), 94-113
- AD Severity Index (ADSI), 101
 - Children's Dermatology Life Quality Index (CDLQI), 110

- Scoring systems (disease severity scales) (*continued*)
- clinical outcome assessments, 112-113
 - clinical outcome assessments and, 112-113
 - concordance of AD signs and symptoms, 111
 - concordance of clinician and patient assessments, 112
 - Dermatitis Family Impact (DFI), 111
 - Dermatology Life Quality Index (DLQI), 109-110
 - Eczema Area and Severity Index (EASI), 97-98, 101, 102, 112
 - global assessments, 98-100
 - Harmonizing Outcome Measures in Eczema (HOME), 95, 103-104
 - modified EASI (mEASI), 98
 - Numerical Rating Scale (NRS)-pruritus, 106-107, 113
 - Patient Oriented Eczema Measure (POEM), 108-109, 113
 - Patient-Reported Global Severity of AD, 104-105
 - Patient-Reported Outcomes (PRO), 103-111
 - Quality of Life (QOL) measures, 103-111
 - Rajka-Langeland (R-L), 100
 - SCORAD (SCORing Atopic Dermatitis), 96, 101, 111-112
 - objective SCORAD (oSCORAD), 97, 101, 102
 - Short Form-36 Health Survey (SF-36), 107-108
 - Six Area Six Sign AD (SASSAD), 100-101, 111
 - skin pain, 105
 - Visual Analogue Scale (VAS)-pruritus, 105-106
 - Visual Response Scale (VRS)-pruritus, 107, 113
- Seborrheic dermatitis (SD), 72-74, 91
- Secukinumab, 212t
- Severe AD, 12-14, 72
 - disease severity scales, 94-113
 - prevalence in United States (by state), 15
- Severity scales. See *Scoring systems (disease severity scales)*.
- Shared decision making, 240-241
- Short Form-36 Health Survey (SF-36), 107-108
- Silk clothing, 42-43
- Six Area Six Sign AD (SASSAD), 100-101, 111
- Skin barrier dysfunction, 21, 22
 - interplay with inflammation, 24
 - moisturizer use and, 122-123
- Skin care, 146, 239
 - bathing, 146, 162-163
 - moisturizers, 143-144
- Skin exposures to irritants and pruritogens, 40t, 41-44
- Skin pain, 105
- Skin prick test (SPT), 93-94
- Sleep disturbance, 67, 125-126, 127
 - antihistamines for, 203
 - cardiovascular disease and, 133-134
- Smoking
 - during pregnancy, 41, 50
 - tobacco smoke exposure, 41, 50-51
 - “Soak and smear” technique, 44, 149
- Soaps, 41, 44, 163
- Specialists in AD, 241-242
- Steroids. See *Corticosteroids*.
- Stress
 - during pregnancy, 39-40
 - management, 226t
- Suicidal ideation, 126
- Sunflower oil, 231-232
- Symptoms of atopic dermatitis, 9, 63, 88t. See also *Clinical presentation of AD*.
 - pruritus, 9, 64, 68
 - xerosis, 64, 68
- Systemic corticosteroids, 197-199. See also *Corticosteroids, systemic*.
- Systemic immunosuppressants, 183-196.
 - See also *Immunosuppressants, systemic*.
- Systemic therapy, oral, 183-207. See also *Oral systemic therapy*.
- Tacrolimus, 152-158
 - in combination with phototherapy (and cautions for), 173
 - dosage and administration, 156-157
 - efficacy, 153
 - indications for, 152-153
 - oral tacrolimus, 196
 - safety and adverse events, 153-156, 159t
 - black box warning for malignancy, 156, 159t
 - in treatment algorithm, 146

- Tanning beds, 178-179
- TCIs. See *Topical calcineurin inhibitors (TCIs)*.
- Team members, 241-244
- Temperature, as factor in AD, 45-47
- TEWL (transepidermal water loss), 21, 22
- Tezepelumab, 212t
- T_h2, T_h17, and T_h22, 24, 30-31, 209-211
- Theophylline, 203
- Therapy for AD. See also *specific treatment modalities*.
- algorithm for mild, moderate, severe disease, 146-147
 - acute treatment, 147
 - basic maintenance, 146
 - moderate-to-severe disease, 146
 - relapses and flares, 146-147
 - biologic therapy, 209-224
 - combination therapy
 - combinations of topical therapies, 143
 - phototherapy with other topical therapies, 173
 - complementary and alternative therapy, 225-238
 - coordinated management, 239-248
 - multidisciplinary team members, 241-244
 - oral systemic therapy, 183-207
 - azathioprine (AZA), 185-187
 - cyclosporine A (CSA), 187-190
 - methotrexate (MTX), 190-196
 - mycophenolate mofetil (MMF), 195-196
 - oral phosphodiesterase-4 (PDE-4) inhibitors (apremilast), 199
 - recommended for acute and/or refractory AD, 183-185, 186
 - systemic corticosteroids, 197-199
 - tacrolimus (oral), 196
 - phototherapy, 169-181
 - topical therapy, 143-168
 - bath treatments, 162-163
 - moisturizers, 143-144
 - prescription emollient devices (PEDs), 144-152
 - topical antihistamines, 164-165
 - topical calcineurin inhibitors (TCIs), 152-158
 - topical corticosteroids, 145-152
- Therapy for AD, topical therapy (*continued*)
- topical phosphodiesterase-4 (PDE-4) inhibitors, 158-162
 - wet-wrap therapy, 163-164
 - written treatment plan, 242
- Thymic stromal lymphopoietin (TSLP), 21, 24, 28-29, 209
- TNF- α , 221
- TNF- α inhibitor (infliximab), 221
- Tobacco smoke exposure, 41, 50-51
- Topical antihistamines, 164-165
- Topical calcineurin inhibitors (TCIs), 152-158.
- See also *Pimecrolimus; Tacrolimus*
 - AAD recommendations, 157-158, 159t
 - action mechanism, 152
 - adverse events, 153-156, 159t
 - in combination with phototherapy (and cautions for), 173
 - in combination with topical corticosteroids, 156-157, 159t
 - dosage and administration, 156-157
 - steroid-sparing with combination therapy, 156, 157
 - efficacy, 153
 - formulations and agents, 152-153
 - indications for, 152-153
 - safety, 153-156
 - black box warning for malignancy, 156, 159t
 - in treatment algorithm, 146
 - warnings and cautions, 156, 173
- Topical corticosteroids. See *Corticosteroids, topical*.
- Topical phosphodiesterase-4 (PDE-4) inhibitors, 158-162.
- See also *Crisaborole (Eucrisa)*.
 - action mechanism, 158
 - contraindications and cautions, 162
 - crisaborole (Eucrisa), 158-162
 - FDA approval for AD, 30
 - dosage and administration, 162
 - efficacy, 158-160, 161
 - safety, 160-162
 - treatment-emergent adverse events (TEAEs), 160-162
- Topical therapy, 143-168. See also *specific treatments*.
- algorithm for, 146-147
 - bath treatments, 146, 162-163
 - combination therapies, 143

- Topical therapy (*continued*)
 - moisturizers, 143-144
 - prescription emollient devices (PEDs), 144-152
 - topical antihistamines, 164-165
 - topical calcineurin inhibitors (TCIs), 152-158
 - topical corticosteroids, 145-152
 - topical phosphodiesterase-4 (PDE-4) inhibitors, 158-162
 - wet-wrap therapy, 163-164
- Tralokinumab, 212t
- Transepidermal water loss (TEWL), 21, 22
- Treatment for AD. *See Therapy for AD.*
- Triamcinolone acetonide, 150t
- Triggers of AD flares
 - aeroallergens, 29
 - avoidance of, 146
- TSLP (thymic stromal lymphopoietin), 21, 24, 28-29, 209
- Tumor necrosis factor alpha (TNF- α), 221
 - inhibitor (infliximab), 221
- Ultraviolet radiation, 47-48
- Ultraviolet A radiation (UVA), 171-172.
 - See also Phototherapy.*
 - combination UVB, 173
 - psoralens and UVA (PUVA), 172
 - dosing guidelines, 174, 175t
 - safety issues, 172, 175, 178
 - side effects, 178
 - UVA-1, 47, 171-172
- Ultraviolet B radiation (UVB), 169-171.
 - See also Phototherapy.*
 - broad-band UVB (BBUVB), 169-170
 - combination UVA, 173
 - dosing guidelines, 174, 176t, 177t
 - excimer laser (308 nm), 171
 - home therapy, 178-179
 - narrow-band UVB (NBUVB), 47, 170-171
 - UVB and crude coal tar (Goeckerman regimen), 171
- Urban vs rural living, 51-52
- Ustekinumab, 212t, 219
- Virgin coconut oil (VCO), 230-231
- Visual Analogue Scale (VAS)-pruritus, 105-106
- Vitamin therapy, 226t, 228
 - vitamin D, 228, 233
 - phototherapy and, 169
- Water
 - bath treatments, 146, 162-163
 - excess hot water when bathing, 43
 - water hardness, 51
- Wet-wrap therapy, 163-164
 - AAD recommendations, 148t
- White dermographism/delayed blanch, 66, 88t
- Wool clothing, 66
- Xerosis, 64, 68
- Yoga, 226t